StockNews.AI
INCR
StockNews.AI
4 hrs

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow

1. InterCure reported NIS 130 million in revenue, showing 15% growth. 2. Positive operating cash flow of NIS 12 million indicates resilience amid challenges. 3. Acquisition of ISHI will enhance U.S. market presence and product offerings. 4. Company achieved eleventh consecutive half of positive Adjusted EBITDA. 5. Regulatory momentum in the U.S. may benefit InterCure's positioning.

Earnings
-2.84%Current Return
VS
+0.51%S&P 500
$1.61510/08 09:07 AM EDTEvent Start
$1.569210/08 12:44 PM EDTLatest Updated
16m saved
Insight
Article

FAQ

Why Bullish?

InterCure's positive revenue growth and cash flow amidst ongoing global challenges suggests solid performance. The successful acquisition of ISHI aligns with their strategic objectives and enhances future revenue potential.

How important is it?

The acquisition and consistent revenue growth strongly position InterCure to capitalize on evolving market opportunities, significantly impacting its stock performance.

Why Long Term?

The potential regulatory changes in the U.S. cannabis market can reshape future growth. The integration of ISHI into operations will likely take time to realize full benefits.

Related Companies

CURLFTLRYAPHA
The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YORK and HERZLIYA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (“InterCure” or the “Company”), today announced its financial and operating results for the first half of 2025. Alexander Rabinovitch, CEO of InterCure, stated: “In the first half of 2025, InterCure delivered revenues of NIS 130 million, achieving positive Adjusted EBITDA for the eleventh consecutive half year period and generating NIS 12 million in positive operating cash flow. This performance underscores the strength of our vertically integrated business model and our ability to navigate a challenging environment, including the impact of the October 7 attack and the ongoing war in Gaza. We continue to work closely with Israeli authorities to secure full compensation for damages to our southern facility. Looking ahead, we are confident in our ability to continue our recovery growth trajectory, expanding our international footprint, and strengthen our leadership in the pharmaceutical cannabis industry, particularly with the strategic acquisition of ISHI, which positions us to capitalize on evolving opportunities in the global cannabis market. At the same time, we are closely monitoring regulatory developments in the U.S. regarding potential rescheduling of cannabis.” First Half 2025 Financial Highlights(All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted) Revenue of NIS 130 million, an increase of 15% compared to the second half of 2024, and an increase of 3% compared to NIS 126 million in the first half of 2024.Net loss of NIS 1.8 million, compared to near break-even in the first half of 2024.Adjusted EBITDA of NIS 12.6 million, representing 10% of revenue, marking the Company’s eleventh consecutive half of positive Adjusted EBITDA.1Positive cash flow from operations of NIS 12 million, compared to negative cash flow of NIS 43 million in the same period last year.Cash on hand of NIS 54 million as of June 30, 2025, compared to NIS 21 million as of June 30, 2024.2Shareholders’ equity of NIS 432 million as of June 30, 2025. Operational and Strategic Highlights As the recovery process progresses, the Company resumed production, importation and sales from the Nir Oz facility, delivering first batches since the October 7, 2023 attack and the ongoing war in Gaza.Launched more than 40 new SKUs during the first half of 2025, marking the first major product launches since October 2023.Received NIS 81 million in compensation advances from Israeli authorities for war-related damages, as part of a total submitted damages3 of NIS 251 million.Continued expansion of Canndoc’s medical cannabis pharmacy chain and growing global demand for InterCure’s pharmaceutical-grade cannabis products.In September 2025, the Company entered into a share purchase agreement to acquire Botanico Ltd. (ISHI), a strategic acquisition expected to strengthen InterCure’s access to premium U.S. genetics, advanced cultivation technologies, and international market opportunities.The Company is closely monitoring regulatory developments in the U.S. regarding potential rescheduling of cannabis and believes that it is well positioned to capitalize on evolving U.S. cannabis landscape, especially following its recent signing of an agreement to acquire ISHI.The Company is closely monitoring regulatory developments in the U.S. regarding potential rescheduling of cannabis and believes that it is well positioned to capitalize on evolving U.S. cannabis landscape, especially following its recent signing of an agreement to acquire ISHI.Under the purchase agreement with respect to ISHI, the Company obtained exclusive supply of premium products under The Flowery™ and leading American brands, which are expected to contribute tens of millions of shekels to the Company’s revenues. About InterCure (dba Canndoc)InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America. For more information, visit: https://www.intercure.co Non-IFRS MeasuresThis press release makes reference to certain non-IFRS financial measures. Adjusted EBITDA, as defined by InterCure, means earnings before interest, income taxes, depreciation, and amortization, adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, and other income, net which included war-related damage compensation from the tax authorities, changes to allowance for credit risk, and impairment of inventory. This measure is not a recognized measure under IFRS, does not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other companies. InterCure’s method of calculating this measure may differ from methods used by other entities and accordingly, this measure may not be comparable to similarly titled measures used by other entities or in other jurisdictions. InterCure uses this measure because it believes it provides useful information to both management and investors with respect to the operating and financial performance of the Company. Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements may include, but are not limited to, the Company’s expected growth, including in Adjusted EBITDA, success of its global expansion plans, its expansion strategy to major markets worldwide, expected receipt of additional compensation from the Israeli government, and the expected completion of the acquisition of ISHI, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s success in executing its global expansion plans (including the pending acquisition of Botanico Ltd. (ISHI)), its continued growth, expected operations and financial results, business strategy, competitive strengths, goals and expansion into major markets worldwide, the impact of the war in Israel and the war in Ukraine, and the conditions of the markets generally. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. regulatory landscape and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, and reliance on the expertise and judgment of our senior management. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 20-F, as well as in the Company’s Form 6-K containing the unaudited condensed consolidated financial statements for the six months ended June 30, 2025, and in other filings that we have made and may make with the Securities and Exchange Commission in the future. Company Contact:InterCure Ltd.Amos Cohen, Chief Financial Officeramos@intercure.co Investor Relations Contact:Arx Investor RelationsNorth American & Israeli Equities Desksintercure@arxhq.com Condensed Consolidated Interim Statements of Financial Position (Unaudited)As of June 30, 2025   As of June 30  NIS in thousands  2025  2024ASSETS               CURRENT ASSETS:       Cash and cash equivalents  51,334   19,899Restricted cash and deposits  2,436   948Trade receivables, net  46,931   61,672Other receivables  119,604   158,045Inventory  148,174   126,466Biological assets  5,269   3,388Financial assets measured at fair value through profit or loss  250   399Total current assets  373,998   370,817        NON-CURRENT ASSETS:       Other receivables  5,824   439Property, plant and equipment and right-of-use asset  105,046   98,611Goodwill  224,778   223,609Deferred tax assets  39,970   27,042Financial assets measured at fair value through profit or loss  2,147   1,922Investment in associate and loan   -   18,447Total non-current assets  377,765   370,070        TOTAL ASSETS  751,763   740,887        LIABILITIES AND EQUITY               CURRENT LIABILITIES:       Short term loan and current maturities  62,767   81,755Trade payables  90,785   83,071Other payables  44,454   39,965Contingent consideration  3,966   4,082Total current liabilities  201,972   208,873        LONG-TERM LIABILITIES:       Long term loans  94,917   51,317Liabilities in respect of employee benefits  973   841Lease liability  21,657   17,741Total long-term liabilities  117,547   69,899        EQUITY:       Share capital, premium and other reserves  675,393   649,013Capital reserve for transactions with controlling shareholder  2,388   2,388Receipts on account of shares  19,591   -Capital reserve for transactions with non-controlling interests  13,561   13,561Accumulated losses  (279,786)  (204,518Equity attributable to owners of the Company  431,147   460,444        Non-controlling interests  1,097   1,671TOTAL EQUITY  432,244   462,115        TOTAL LIABILITIES AND EQUITY  751,763   740,887 Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income (Unaudited)   For the 6-monthsended on June 30  Year endedDecember 31  NIS in thousands  2025  2024  2024         Revenue  130,011   125,733   238,845Cost of revenue before fair value adjustments  91,449   85,291   203,252            Gross income before impact of changes in fair value  38,562   40,442   35,593            Unrealized changes to fair value adjustments of biological assets  1,661   1,218   6,458Loss from fair value changes realized in the current year  2,005   1,029   11,818            Gross Profit  38,218   40,631   30,233            Research and development expenses  191   219   414General and administrative expenses  14,302   18,374   53,669Sales and marketing expenses  26,115   27,454   54,225Other expenses, net  (9,074)  (16,414)  (12,807Changes in the fair value of financial assets through profit or loss, net.  83   (201)  (341Share based payments  885   686   2,281            Operating Profit  5,716   10,513   (67,208                        Financing income  2,356   1,031   2,747Financing expenses  10,369   10,070   22,862            Financing expenses (income), net  8,013   9,039   20,115            Profit before tax on income  (2,297)  1,474   (87,323            Tax (expense) benefit  485   (1,480)  14,530Total comprehensive Profit (loss)  (1,812)  (6)  (72,793            Profit (loss) attributable to:           Owners of the Company  (1,704)  1,433   (67,795Non-controlling interests  (108)  (1,439)  (4,998Total  (1,812)  (6)  (72,793            Earnings per share           Basic earnings (loss)  (0.03)  0.03   (1.48Diluted earnings (loss)  (0.03)  0.03   (1.48 Non-IFRS Financial Measures Total comprehensive Profit (loss)  (1,812)  (6)  (72,793)Interest / Financing expense (income) net  8,013   9,039   20,115 Tax expenses (benefit)  (485)  1,480   (14,530)Depreciation and amortization  8,451   6,337   15,371 EBITDA  14,167   16,850   (51,837)Share-based payment expenses  885   686   2,281 Other income, net  (9,074)  (16,414)  (12,807)War-related damage compensation from the tax authorities  9,019   16,830   42,468 Changes to allowance for credit risk  (2,844)      16,878 Impairment of inventory   -    -   15,960 Changes in the fair value of financial assets through profit or loss, net  83   (201)  (341)Fair value adjustment to inventory  344   (189)  5,360 Adjusted EBITDA  12,580   17,562   17,962  For More Financial Information:For a comprehensive understanding of the Company’s financial reports and related management’s discussion and analysis for applicable periods, please review the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2024, and the Company’s Form 6-K containing the unaudited condensed consolidated financial statements for the six months ended June 30, 2025, both available on the Company’s EDGAR profile at https://www.sec.gov/edgar 1 Adjusted EBITDA means net income (loss) before interest, taxes, depreciation and amortization adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, and other expenses (or income). Other income, net includes war-related damage compensation from the tax authorities, changes to allowance for credit risk and impairment of inventory.2 Including restricted cash and deposits.3 The claim is not final and remains subject to adjustment. The total amount claimed may be increased as further information becomes available.

Related News